Orexigen® Pipeline
Orexigen is developing two compounds, each with specific characteristics to combat obesity.
None of the Orexigen product candidates have been approved for sale.
Contrave (bupropion SR/naltrexone SR) and Empatic (zonisamide SR/bupropion SR) are still being evaluated in clinical trials.
Clinical trials for Contrave and Empatic are not currently enrolling new patients.